ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Daiichi Sankyo Co Ltd (PK)

Daiichi Sankyo Co Ltd (PK) (DSKYF)

28,655
0,00
( 0,00% )
Aktualisiert: 13:15:23

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
28,655
Gebot
27,90
Fragen
30,35
Volumen
-
0,00 Tagesbereich 0,00
24,56 52-Wochen-Bereich 44,64
Marktkapitalisierung
Handelsende
28,655
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
54.220
Ausgegebene Aktien
1.916.787.029
Dividendenrendite
16,356.41%
Kurs-Gewinn-Verhältnis
0,27
Gewinn pro Aktie (EPS)
104,72
Erlöse
1,63T
Nettogewinn
200,73B

Über Daiichi Sankyo Co Ltd (PK)

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Biolog/vaccines
Hauptsitz
Chuo, Tokyo, Jpn
Gegründet
2005
Daiichi Sankyo Co Ltd (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker DSKYF. The last closing price for Daiichi Sankyo (PK) was US$28,66. Over the last year, Daiichi Sankyo (PK) shares have traded in a share price range of US$ 24,56 to US$ 44,64.

Daiichi Sankyo (PK) currently has 1.916.787.029 shares in issue. The market capitalisation of Daiichi Sankyo (PK) is US$54,93 billion. Daiichi Sankyo (PK) has a price to earnings ratio (PE ratio) of 0.27.

DSKYF Neueste Nachrichten

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of...

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources PR Newswire PARSIPPANY, N.J., June 28, 2011 PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc...

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. PR Newswire PARSIPPANY, N.J., April 4, 2011 PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced...

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest...

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest Clinical...

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology PR Newswire WOBURN, Massachusetts, October 12, 2010 WOBURN, Massachusetts, October 12, 2010 /PRNewswire/ -- ArQule, Inc...

Patients with Hypertension at Risk Due to Physician Inertia

Patients with Hypertension at Risk Due to Physician Inertia - New Supporting Hypertension Awareness and Research Europe-wide (SHARE) Survey Reports Findings at the 20th Annual Society of the...

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban - Innovative Once-Daily Oral Factor Xa Inhibitor Submitted for Approval in Japan PR Newswire TOKYO, April...

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Bolsters Company's Expertise in Areas of Oncology and Hematology PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
12.6051026.0530.3524.5654170727.01660574CS
4-0.945-3.1925675675729.630.3524.5614952226.98464896CS
12-2.505-8.0391527599531.1634.7524.565422027.2258675CS
26-10.085-26.032524522538.7444.6424.562521027.78419181CS
52-2.025-6.6003911342930.6844.6424.562086029.31159856CS
1565.71524.912816041822.9444.6419.451166929.29861034CS
260-37.965-56.987391173866.6295.9617.61858829.1742701CS

DSKYF - Frequently Asked Questions (FAQ)

What is the current Daiichi Sankyo (PK) share price?
The current share price of Daiichi Sankyo (PK) is US$ 28,655
How many Daiichi Sankyo (PK) shares are in issue?
Daiichi Sankyo (PK) has 1.916.787.029 shares in issue
What is the market cap of Daiichi Sankyo (PK)?
The market capitalisation of Daiichi Sankyo (PK) is USD 54,93B
What is the 1 year trading range for Daiichi Sankyo (PK) share price?
Daiichi Sankyo (PK) has traded in the range of US$ 24,56 to US$ 44,64 during the past year
What is the PE ratio of Daiichi Sankyo (PK)?
The price to earnings ratio of Daiichi Sankyo (PK) is 0,27
What is the cash to sales ratio of Daiichi Sankyo (PK)?
The cash to sales ratio of Daiichi Sankyo (PK) is 0,03
What is the reporting currency for Daiichi Sankyo (PK)?
Daiichi Sankyo (PK) reports financial results in JPY
What is the latest annual turnover for Daiichi Sankyo (PK)?
The latest annual turnover of Daiichi Sankyo (PK) is JPY 1,63T
What is the latest annual profit for Daiichi Sankyo (PK)?
The latest annual profit of Daiichi Sankyo (PK) is JPY 200,73B
What is the registered address of Daiichi Sankyo (PK)?
The registered address for Daiichi Sankyo (PK) is 3-5-1 NIHONBASHI-HONCHO, CHUO-KU, CHUO, TOKYO, 103-8426
What is the Daiichi Sankyo (PK) website address?
The website address for Daiichi Sankyo (PK) is www.daiichisankyo.co.jp
Which industry sector does Daiichi Sankyo (PK) operate in?
Daiichi Sankyo (PK) operates in the PHARMACEUTICAL BIOLOG/VACCINES sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
MDCNMedican Enterprises Inc (PK)
US$ 0,0001
(9.900,00%)
5,03M
DMTKQDermTech Inc (CE)
US$ 0,0001
(9.900,00%)
5k
AHIIAmerican Heritage International Inc (CE)
US$ 0,0001
(9.900,00%)
401
COSGCosmos Group Holdings Inc (PK)
US$ 0,0001
(9.900,00%)
100,8M
TTCMTautachrome Inc (CE)
US$ 0,0001
(9.900,00%)
407,67k
CONNQConns Inc (CE)
US$ 0,000001
(-99,98%)
250
GRTSQGritstone bio Inc (CE)
US$ 0,000001
(-99,90%)
6,97k
EGOCEnergy One Corporation (CE)
US$ 0,000001
(-99,90%)
21,8k
FUVVArcimoto Inc (CE)
US$ 0,000001
(-99,50%)
639
TGGITrans Global Group Inc (CE)
US$ 0,000001
(-99,50%)
150k
COSGCosmos Group Holdings Inc (PK)
US$ 0,0001
(9.900,00%)
100,8M
ASIIAccredited Solutions Inc (PK)
US$ 0,0005
(0,00%)
54,28M
PDGOParadigm Oil and Gas Inc (PK)
US$ 0,0002
(0,00%)
52,12M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0,00355
(2,90%)
38M
RITEMineralRite Corporation (PK)
US$ 0,0016
(14,29%)
36,49M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock